866-997-4948(US-Canada Toll Free)

Epithelial Ovarian Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Ovarian Cancer

No. of Pages : 98 Pages

 

Global Markets Directs, \'Epithelial Ovarian Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Epithelial Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer. 

 

Epithelial Ovarian Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

 

  • A snapshot of the global therapeutic scenario for Epithelial Ovarian Cancer.
  • A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Epithelial Ovarian Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

 

  • Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Epithelial Ovarian Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Epithelial Ovarian Cancer 10
Epithelial Ovarian Cancer Therapeutics under Development by Companies 12
Epithelial Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Epithelial Ovarian Cancer Therapeutics - Products under Development by Companies 19
Epithelial Ovarian Cancer Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Epithelial Ovarian Cancer Therapeutics Development 21
Boehringer Ingelheim GmbH 21
Amgen Inc. 22
GlaxoSmithKline plc 23
Oxford BioMedica plc 24
Novartis AG 25
Astellas Pharma Inc. 26
Chong Kun Dang Pharmaceutical 27
Bayer AG 28
Array BioPharma Inc. 29
Prima BioMed Limited 30
Synta Pharmaceuticals Corp. 31
Viral Genetics, Inc. 32
Epithelial Ovarian Cancer - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
trebananib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
sorafenib tosylate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
elesclomol - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TroVax - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MEK-162 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CVac - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
linsitinib + [paclitaxel] - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Docetaxel + Yondelis + Pegfilgrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Therapeutic allogeneic lymphocytes program - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
trebananib + [doxorubicin liposomal] - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
trebananib + [topotecan hydrochloride] - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
iboctadekin + [doxorubicin liposomal] 63
- Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
bevacizumab + [irinotecan hydrochloride] - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SJG-136 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
belinostat + [carboplatin] - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Docetaxel + Gemcitabine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
vandetanib + [docetaxel] - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
nintedanib + [carboplatin] + [doxorubicin] - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
belotecan hydrochloride - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Dendritic Cell 006 Vaccine - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pazopanib hydrochloride + [paclitaxel] - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
hydroxychloroquine + sorafenib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Epithelial Ovarian Cancer Therapeutics - Drug Profile Updates 81
Epithelial Ovarian Cancer Therapeutics - Discontinued Products 90
Epithelial Ovarian Cancer Therapeutics - Dormant Products 91
Epithelial Ovarian Cancer - Product Development Milestones 94
Featured News & Press Releases 94
Nov 14, 2012: Prima BioMed Releases Interim Immune Monitoring Data From CVac Phase II Clinical Trial 94
Oct 15, 2012: Prima BioMed Announces Positive Interim Data From CAN-003 Trial Of CVac For Ovarian Cancer 94
Oct 08, 2012: Scottish Medicines Consortium Rejects Roche\'s Avastin For Ovarian Cancer 95
Sep 20, 2012: Roche\'s Avastin Obtains Positive Opinion From CHMP To Treat Various Cancers 95


Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 98
Disclaimer 98

List of Table


Number of Products Under Development for Epithelial Ovarian Cancer, H1 2013 10
Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Investigation by Universities/Institutes, H1 2013 20
Boehringer Ingelheim GmbH, H1 2013 21
Amgen Inc., H1 2013 22
GlaxoSmithKline plc, H1 2013 23
Oxford BioMedica plc, H1 2013 24
Novartis AG, H1 2013 25
Astellas Pharma Inc., H1 2013 26
Chong Kun Dang Pharmaceutical, H1 2013 27
Bayer AG, H1 2013 28
Array BioPharma Inc., H1 2013 29
Prima BioMed Limited, H1 2013 30
Synta Pharmaceuticals Corp., H1 2013 31
Viral Genetics, Inc., H1 2013 32
Assessment by Monotherapy Products, H1 2013 33
Assessment by Combination Products, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 38
Epithelial Ovarian Cancer Therapeutics - Drug Profile Updates 81
Epithelial Ovarian Cancer Therapeutics - Discontinued Products 90
Epithelial Ovarian Cancer Therapeutics - Dormant Products 91
Epithelial Ovarian Cancer Therapeutics - Dormant Products (Contd..1) 92
Epithelial Ovarian Cancer Therapeutics - Dormant Products (Contd..2) 93

List of Chart


Number of Products under Development for Epithelial Ovarian Cancer, H1 2013 10
Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 14
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Assessment by Monotherapy Products, H1 2013 33
Assessment by Combination Products, H1 2013 34
Assessment by Route of Administration, H1 2013 35
Assessment by Stage and Route of Administration, H1 2013 36
Assessment by Molecule Type, H1 2013 37
Assessment by Stage and Molecule Type, H1 2013 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *